B
Bull
Bull · 25%REGN
$785.14
Scenario price
$782.040
-8.602 (-1.10%)At close
Loading chart…
- High
- 797.430
- Open
- 793.820
- VWAP
- 786.86
- Volume
- 487.52K
- Mkt Cap
- 115.79B
- Low
- 781.120
- Amount
- 383.61M
- EV/EBITDA, TTM
- 12.19
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
AI analysis of Regeneron Pharmaceuticals Inc (REGN)
BuyRegeneron Pharmaceuticals Inc is a good buy right now, trading at $790.74 with a strong forward P/E of 14.51, indicating potential for earnings growth. The recent positive Phase 3 trial results for Pasatru highlight significant efficacy, which could drive future revenue. Additionally, hedge funds have increased their buying activity by 167% over the last quarter, suggesting strong institutional confidence. However, the RSI is at 69.33, indicating that the stock may be nearing overbought territory, which is a risk to consider.
Analyst Ratings (26)
+3.38% upside
Buy
13 Buy
12 Hold
1 Sell
Current: 782.04
Low
637.00
Average
808.50
High
—
BofA
Buy
$908
2026-10-12
BofA
2026-10-12
Price Target
$908
Buy
RBC Capital
Sector Perform
$810
2026-10-08
RBC Capital
2026-10-08
Price Target
$810
Sector Perform
Truist
Buy
$780
2026-10-07
Truist
2026-10-07
Price Target
$780
Buy
Morgan Stanley
Equal Weight
$779
2026-10-07
Morgan Stanley
2026-10-07
Price Target
$779
Equal Weight
JPMorgan
Overweight
$950
2026-10-06
JPMorgan
2026-10-06
Price Target
$950
Overweight
Valuation Metrics
The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN) is 14.51, compared to its 5-year average forward P/E of 16.98.
Alphio AI Price Scenarios for REGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding REGN
Events Timeline
News
5.010-19FoolWeight Loss Drug Market Rapid Growth
8.510-19stocktwitsModerna and Merck Present Phase 3 Melanoma Findings for Personalized Cancer Treatment
9.510-17FoolRegeneron Faces Sales Challenges Despite Dupixent Growth
8.510-16NewsfilterPositive Opinion for Libtayo Dosing Adjustment
6.010-15CNBCLatest Wall Street Rating Updates
REGN FAQ — answered by Alphio AI
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Regeneron Pharmaceuticals Inc is a good buy right now, trading at $790.74 with a strong forward P/E of 14.51, indicating potential for earnings growth. The recent positive Phase 3 trial results for Pasatru highlight significant efficacy, which could drive future revenue. Additionally, hedge funds have increased their buying activity by 167% over the last quarter, suggesting strong institutional confidence. However, the RSI is at 69.33, indicating that the stock may be nearing overbought territory, which is a risk to consider.
26 analysts cover REGN: 13 rate it Buy, 12 Hold and 1 Sell. The average price target is 808.50.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.